


Ask a doctor about a prescription for Exferana
Deferasirox
Exferana contains the active substance deferasirox. It is an iron chelator, i.e. a medicine used to remove excess iron (also known as iron overload) from the body. Exferana captures and removes excess iron, which is then mainly excreted in the stool.
Repeated blood transfusions may be necessary for patients with various types of anemia (e.g. thalassemia, sickle cell anemia, or myelodysplastic syndromes). However, repeated blood transfusions can cause iron to accumulate. This happens because blood contains iron, and the body does not have natural methods to remove excess iron received during transfusions. In patients with thalassemia who are not dependent on blood transfusions, iron overload may also develop over time, mainly due to increased iron absorption from food, as a reaction to a low number of red blood cells. Over time, excessive iron can cause damage to important organs, such as the liver and heart. To remove excess iron and reduce the risk of organ damage, iron chelators are used. Exferana is used to treat chronic iron overload due to frequent blood transfusions in patients with severe beta thalassemia aged 6 years and older. Exferana is also used to treat chronic iron overload when treatment with deferoxamine is contraindicated or inappropriate, in patients with severe beta thalassemia with iron overload due to infrequent blood transfusions, in patients with other types of anemia, and in patients aged 2 to 5 years. Exferana is also used when deferoxamine therapy is contraindicated or insufficient, in the treatment of patients aged 10 years and older with iron overload in the course of thalassemia syndromes, independent of blood transfusions.
Before starting treatment with Exferana, you should discuss it with your doctor or pharmacist:
If any of the above applies to you, you should immediately inform your doctor.
During treatment, you will undergo regular blood and urine tests. Their purpose is to monitor the amount of iron in your body (ferritin levels in the blood) to check how Exferana works. Blood tests also allow monitoring of kidney function (creatinine levels in the blood, protein in the urine) and liver function (increased aminotransferase activity in the blood). Your doctor may order a kidney biopsy if they suspect significant kidney damage. You may also undergo an MRI (magnetic resonance imaging) to determine the amount of iron in the liver. Your doctor will take into account the results of these tests when determining the optimal dose of Exferana for you and when deciding whether to stop taking Exferana. As a precaution, annual vision and hearing tests will be performed during treatment.
Tell your doctor or pharmacist about all medicines you are taking, have recently taken, or plan to take, including:
Your doctor may order additional tests to monitor the levels of some of these medicines in your blood.
Exferana can be used in patients aged 65 years and older at the same doses as in other adult patients. In elderly patients, more side effects may occur (especially diarrhea) than in younger patients. Patients in this age group should be closely monitored by their doctor to detect possible side effects that may require dose adjustment.
Exferana can be used in children and adolescents aged 2 years and older who receive regular blood transfusions and in children and adolescents aged 10 years and older who do not receive regular blood transfusions. As the patient grows, the doctor will adjust the dose of the medicine. Exferana is not recommended for children under 2 years of age.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor before taking this medicine. Exferana is not recommended during pregnancy unless there is a clear need for treatment. If you are currently taking oral contraceptives or using contraceptive patches to prevent pregnancy, you should use an additional method of contraception, or a different type of contraception (e.g. condoms), as deferasirox may reduce the effectiveness of oral and patch contraceptives. During treatment with Exferana, breastfeeding is not recommended.
If you experience dizziness while taking Exferana, do not drive or operate machinery until you feel normal again.
If you have been diagnosed with an intolerance to some sugars, consult your doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per dose, which means it is considered "sodium-free".
Treatment with Exferana will be supervised by a doctor with experience in treating patients with iron overload due to blood transfusions. This medicine should always be taken exactly as prescribed by your doctor. If you are unsure, consult your doctor or pharmacist.
In all patients, the dose of Exferana is based on body weight. Your doctor will calculate the required dose and tell you how many tablets to take per day.
Deferasirox is also available in a formulation for the preparation of an oral suspension. If you switch from tablets to an oral suspension, your dose may need to be adjusted.
Taking Exferana at the same time every day will also help you remember to take your medicine. If you are unable to swallow the tablets whole, Exferana tablets can be crushed and sprinkled on a soft, non-acidic food such as yogurt or applesauce. You should consume the dose immediately with the food and not store it for later use.
You should continue to take Exferana every day for as long as your doctor recommends. This is a long-term treatment that may last several months or years. Your doctor will regularly check your health to see if the treatment is working (see also section 2: "Monitoring Exferana treatment"). If you have questions about the duration of treatment with Exferana, consult your doctor.
If you take more Exferana than recommended or if someone else accidentally takes the tablets, you should immediately consult your doctor or go to the nearest hospital. You should show the doctor the packaging of the medicine. Immediate treatment may be necessary. You may experience symptoms such as abdominal pain, diarrhea, nausea, and vomiting, as well as kidney or liver problems, which can be serious.
If you miss a dose, take it as soon as possible on the same day. Take the next dose at the usual time. Do not take a double dose the next day to make up for the missed tablet (tablets).
Do not stop taking Exferana unless your doctor tells you to. If you stop treatment, excess iron will no longer be removed from your body (see also "How long to take Exferana").
Like all medicines, Exferana can cause side effects, although not everybody gets them. Most side effects are mild to moderate and usually go away after a few days or weeks of treatment.
These side effects occur uncommonly(may affect up to 1 in 100 people) or rarely(may affect up to 1 in 1,000 people).
These side effects occur uncommonly.
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Frequency not known(cannot be estimated from the available data)
If you experience any side effects, including any not listed in this leaflet, you should inform your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products: Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
The active substance of Exferana is deferasirox. Each Exferana 90 mg coated tablet contains 90 mg of deferasirox. Each Exferana 180 mg coated tablet contains 180 mg of deferasirox. Each Exferana 360 mg coated tablet contains 360 mg of deferasirox. The other ingredients are: Tablet core: microcrystalline cellulose (type 101 and 102), povidone K-30, crospovidone (type A and B), poloxamer 188, colloidal silicon dioxide, magnesium stearate Coating: hypromellose (E 464), lactose monohydrate, titanium dioxide (E 171), triacetin, aluminum lake of indigo carmine (E 132)
Exferana is available in the form of coated tablets. The tablets are oval and biconvex.
Single packs containing 30 or 90 coated tablets. The blister pack may be perforated or non-perforated. Not all pack sizes or strengths may be marketed.
VIPHARM S.A. ul. A. i F. Radziwiłłów 9 05-850 Ożarów Mazowiecki Poland
Synthon Hispania S.L. Calle Castello 1 08830 Sant Boi de Llobregat Barcelona Spain Synthon BV Microweg 22 6545 CM Nijmegen Netherlands
Netherlands Exferana 90 mg, filmomhulde tabletten Exferana 180 mg filmomhutten tabletten Exferana 360 mg filmomhutten tabletten Czech Republic Exferana Hungary Exferana 90 mg filmtabletta Exferana 180 mg filmtabletta Exferana 360 mg filmtabletta Poland Exferana Slovakia Exferana 90 mg Exferana 180 mg Exferana 360 mg
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Exferana – subject to medical assessment and local rules.